Clinical Trials | March 09, 2026
DiaMedica bags Health Canada nod for Phase 2 preeclampsia trial
DiaMedica said it plans to launch the trial later in 2026
DiaMedica said it plans to launch the trial later in 2026
Our clinical data suggests ProLectin-M demonstrated earlier reductions in viral shedding compared with placebo with a favorable safety profile
Achondroplasia, a rare genetic disorder, causes skeletal dysplasia and often increases the risk of muscular, neurological, and cardiorespiratory complications
The decision marks a pivotal moment for the Massachusetts-based biotech giant
PEACE-3 is a strong example of how academic cooperative research can help advance progress for complex diseases such as metastatic prostate cancer
The initiative, funded entirely under the company’s CSR programme, is expected to reach over a million lives
Asahi Kasei Pharma receives worldwide exclusive rights for the research, development, manufacturing, and marketing of the active ingredients
CagriSema produced a 23% weight loss at 84 weeks, versus 25.5% for tirzepatide
The move follows encouraging Phase I data and a series of regulatory wins from the U.S. Food and Drug Administration
The MoU lays the groundwork for deep academic and research collaboration in pharmaceutical technologies
Subscribe To Our Newsletter & Stay Updated
